A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

NCT07592910 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Prostate Cancer (Adenocarcinoma)

Interventions

DRUG: Mevrometostat
DRUG: Enzalutamide

Sponsor

Prostate Cancer Clinical Trials Consortium

Collaborators

[object Object]
[object Object]
[object Object]